Clinical Trials
42 trialsPhase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
The Affiliated Hospital of Qingdao University
VAROCE
Centre Oscar Lambret
PEMBIB
Gustave Roussy, Cancer Campus, Grand Paris
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Washington University School of Medicine
Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Memorial Sloan Kettering Cancer Center
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
China Medical University Hospital
ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer
Belgian Gynaecological Oncology Group
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
University of Texas Southwestern Medical Center
Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
CHIVA
ARCAGY/ GINECO GROUP
LAM
IRCCS Multimedica
LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
Wake Forest University Health Sciences
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
Yale University
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
Hoosier Cancer Research Network
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Barbara Ann Karmanos Cancer Institute
REFRACT
University Hospital, Limoges
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Nintedanib in Patients With Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
N3
Royal Marsden NHS Foundation Trust
NIPAWILMA
University Hospital, Essen
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
Roswell Park Cancer Institute
AIO-KRK-0111
Martin-Luther-Universität Halle-Wittenberg
Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics
Centro Nacional de Investigaciones Oncologicas CARLOS III
Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
M.D. Anderson Cancer Center
METRO-BIBF
University College, London
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
Duke University
Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
University of Alabama at Birmingham
NOA-12: BIBF1120 and R-RT in Glioblastoma
University Hospital Heidelberg
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
Roswell Park Cancer Institute
A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy
AHS Cancer Control Alberta
BARIS
University of Cologne
VENUS-1
Aktion Bronchialkarzinom e.V.
Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
Samsung Medical Center
BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
National Taiwan University Hospital
VENUS-2
Aktion Bronchialkarzinom e.V.
BIBF 1120 for Recurrent High-Grade Gliomas
Dana-Farber Cancer Institute
BIBF 1120 in Recurrent Glioblastoma Multiforme
Rigshospitalet, Denmark